Effects of recombinant human granulocyte-colony stimulating factor on neutropenic mice infected with Candida albicans: acceleration of recovery from neutropenia and potentiation of anti-C. albicans resistance

Mycoses ◽  
2009 ◽  
Vol 37 (3-4) ◽  
pp. 93-99 ◽  
Author(s):  
M. Hamood ◽  
P. F. Bluche ◽  
C. Vroey ◽  
F. Corazza ◽  
W. Bujan ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

scholarly journals Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole.

1997 ◽  
Vol 41 (7) ◽  
pp. 1575-1578 ◽  
Author(s):  
U Natarajan ◽  
E Brummer ◽  
D A Stevens
Keyword(s):  
Candida Albicans ◽  
Polymorphonuclear Neutrophils ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Fungal Exposure ◽  
Before And After ◽  
Stimulating Factor ◽  
Strain Dependent

The effect of granulocyte colony-stimulating factor (GCSF) treatment of polymorphonuclear neutrophils (PMN) in vitro was studied with respect to their candidacidal activity. The candidacidal activity of PMN was found to be significantly increased when they were pretreated with GCSF. Fluconazole (1 microg/ml) was found to be highly fungistatic (90%) for Candida albicans Sh27 and collaborated with PMN for significantly increased killing. Collaborative killing by PMN significantly increased when they were treated with GCSF before and after fungal exposure. The enhancing activities of GCSF required optimization of the GCSF dose and were thus inoculum and strain dependent.

scholarly journals Treatment of Intra-Abdominal Abscesses Caused by Candida albicans with Antifungal Agents and Recombinant Murine Granulocyte Colony-Stimulating Factor

2003 ◽  
Vol 47 (12) ◽  
pp. 3688-3693 ◽  
Author(s):  
Alieke G. Vonk ◽  
Mihai G. Netea ◽  
Johan H. van Krieken ◽  
Paul E. Verweij ◽  
Jos W. M. van der Meer ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Amphotericin B ◽  
Antifungal Agent ◽  
Antifungal Agents ◽  
Antifungal Treatment ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Abdominal Abscesses ◽  
Stimulating Factor ◽  
Therapeutic Administration

ABSTRACT The aim of the present study was to assess the influence of immunomodulation of host defense with recombinant murine granulocyte colony-stimulating factor (rmG-CSF) on intra-abdominal abscesses caused by Candida albicans. Mice received prophylaxis or therapy with 1 μg of rmG-CSF/day in the presence or absence of antifungal treatment consisting of amphotericin B (0.75 mg/kg of body weight/day) or fluconazole (50 mg/kg/day). The number of Candida CFU in abscesses was significantly reduced (P < 0.05) in mice receiving rmG-CSF prophylaxis (day −1 or day −1 through 2) compared with controls on day 8 of infection. Administration of rmG-CSF therapy alone (for 5 days starting on day 4 of infection) had no influence on the number of Candida CFU in abscesses. Amphotericin B treatment was significantly more effective than fluconazole treatment (3.41 log CFU/abscesses; 95% confidence interval [CI], 3.17 log CFU/abscesses; 3.65 versus 3.90 log CFU/abscesses; 95% CI, 3.66 log CFU/abscesses, 4.16 log CFU/abscesses; P < 0.05). Therapeutic administration of rmG-CSF in conjunction with an antifungal agent showed a tendency towards a further reduction of Candida CFU in abscesses than antifungal treatment only. In conclusion, in this experimental model of intra-abdominal Candida abscesses, rmG-CSF administration did not have a detrimental influence on the course of infection. Amphotericin B treatment was most effective, and additional rmG-CSF therapy did not antagonize the effect of antifungal treatment. In contrast, addition of rmG-CSF therapy to antifungal treatment might further enhance the beneficial effect of the antifungal agent.

scholarly journals Activity of Voriconazole, a New Triazole, Combined with Neutrophils or Monocytes against Candida albicans: Effect of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor

1998 ◽  
Vol 42 (4) ◽  
pp. 907-910 ◽  
Author(s):  
Shefali Vora ◽  
Nayanatara Purimetla ◽  
Elmer Brummer ◽  
David A. Stevens
Keyword(s):  
Candida Albicans ◽  
Weight Basis ◽  
Polymorphonuclear Neutrophils ◽  
Resistant Isolate ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Gm Csf ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Stimulating Factor

ABSTRACT The antifungal activity of voriconazole (VCZ) was tested againstCandida albicans in the absence or presence of polymorphonuclear neutrophils (PMN) or monocytes. In some experiments, VCZ was compared to fluconazole (FCZ). On a weight basis, VCZ was 10-fold more efficacious than FCZ against C. albicans Sh27. Against an FCZ-resistant isolate, VCZ at 1 μg/ml produced the same fungistasis as FCZ at 20 μg/ml. VCZ at 0.1 μg/ml collaborated with PMN for enhanced killing to the same extent as FCZ at 1.0 μg/ml. Granulocyte-colony-stimulating factor (G-CSF) enhanced the candidacidal activity of PMN, and it increased the collaboration of PMN with VCZ for killing. Granulocyte-macrophage (GM)-CSF also significantly enhanced both the killing by PMN and the collaboration of PMN with VCZ for killing. VCZ collaborated with monocytes for enhanced killing ofC. albicans Sh27, and GM-CSF increased this collaboration. Taken together, these data show that VCZ is more potent than FCZ against C. albicans isolates, alone and in collaboration with PMN or monocytes for enhanced killing. In addition, G-CSF- or GM-CSF-activated PMN and monocytes have enhanced collaboration with VCZ compared to that of unstimulated phagocytes with VCZ.

Sign in / Sign up

Export Citation Format

Share Document